Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

Trials (Dec 2019)

Affiliations

Wesley de Jong: Department of Viroscience, Erasmus MC
Joeri Aerts: Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel
Sabine Allard: Department of Internal Medicine and Infectious Diseases, Universitair Ziekenhuis Brussel
Christian Brander: Infectious Diseases Unit, IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol
Jozefien Buyze: Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine and
Eric Florence: Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine and
Eric van Gorp: Department of Viroscience, Erasmus MC
Guido Vanham: Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine and
Lorna Leal: Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Beatriz Mothe: Infectious Diseases Unit, IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol
Kris Thielemans: Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel
Montse Plana: Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Félipe Garcia: Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Rob Gruters: Department of Viroscience, Erasmus MC
on behalf of the iHIVARNA consortium

Abstract

Following publication of the original article [1], we have been notified that end note would need to be adjusted.